−1.66USD
−67.68 MUSD
34.77 M
About Cabaletta Bio, Inc.
Sector
Industry
CEO
Steven Nichtberger
Website
Headquarters
Philadelphia
Employees (FY)
103
Founded
2017
ISIN
US12674W1099
FIGI
BBG00MJ3BKW2
Cabaletta Bio, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of CABA is 13.97 USD — it has decreased by 7.79% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Cabaletta Bio, Inc. stocks are traded under the ticker CABA.
Cabaletta Bio, Inc. is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
CABA stock is 9.86% volatile and has beta coefficient of 2.40. Check out the list of the most volatile stocks — is Cabaletta Bio, Inc. there?
One year price forecast for Cabaletta Bio, Inc. has a max estimate of 50.00 USD and a min estimate of 25.00 USD.
CABA earnings for the last quarter are −0.37 USD per share, whereas the estimation was −0.40 USD resulting in a 8.29% surprise. The estimated earnings for the next quarter are −0.39 USD per share. See more details about Cabaletta Bio, Inc. earnings.
Yes, you can track Cabaletta Bio, Inc. financials in yearly and quarterly reports right on TradingView.
CABA stock has fallen by 22.52% compared to the previous week, the month change is a 21.38% fall, over the last year Cabaletta Bio, Inc. has showed a 65.72% increase.
CABA net income for the last quarter is −20.89 M USD, while the quarter before that showed −16.45 M USD of net income which accounts for −26.98% change. Track more Cabaletta Bio, Inc. financial stats to get the full picture.
Today Cabaletta Bio, Inc. has the market capitalization of 598.61 M, it has increased by 9.40% over the last week.
No, CABA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, CABA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Cabaletta Bio, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 103.00 employees. See our rating of the largest employees — is Cabaletta Bio, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Cabaletta Bio, Inc. technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Cabaletta Bio, Inc. stock shows the buy signal. See more of Cabaletta Bio, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Cabaletta Bio, Inc. future price: according to them, CABA price has a max estimate of 50.00 USD and a min estimate of 25.00 USD. Read a more detailed Cabaletta Bio, Inc. forecast: see what analysts think of Cabaletta Bio, Inc. and suggest that you do with its stocks.